Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial

Yongjun Wang, Claiborne Johnston, Philip M Bath, Xia Meng, Jing Jing, Xuewei Xie, Anxin Wang, Yuesong Pan, Anding Xu, Qiang Dong, Yilong Wang, Xingquan Zhao, Zixiao Li, Hao Li, CHANCE-2 Investigators, Yongjun Wang, Claiborne Johnston, Philip M Bath, Xia Meng, Jing Jing, Xuewei Xie, Anxin Wang, Yuesong Pan, Anding Xu, Qiang Dong, Yilong Wang, Xingquan Zhao, Zixiao Li, Hao Li, CHANCE-2 Investigators

Abstract

Background: In patients with a minor ischaemic stroke or transient ischaemic attack (TIA), separate trials have shown that dual antiplatelet therapy with clopidogrel plus aspirin (clopidogrel-aspirin) or ticagrelor plus aspirin (ticagrelor-aspirin) are more effective than aspirin alone in stroke secondary prevention. However, these two sets of combination have not been directly compared. Since clopidogrel was less effective in stroke patients who were CYP2C19 loss-of-function (LOF) allele carriers, whether ticagrelor-aspirin is clinically superior to clopidogrel-aspirin in this subgroup of patients with stroke is unclear.

Aim: To describe the rationale and design considerations of the Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE-2) trial.

Design: CHANCE-2 is a randomised, double-blind, double-dummy, placebo-controlled, multicentre trial that compares two dual antiplatelet strategies for minor stroke or TIA patients who are CYP2C19 LOF allele carriers: ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily on days 2-90) or clopidogrel (300 mg loading dose on day 1 followed by 75 mg daily on days 2-90), plus open-label aspirin with a dose of 75-300 mg on day 1 followed by 75 mg daily on day 2-21. All will be followed for 1 year.

Study outcomes: The primary efficacy outcome is any stroke (ischaemic or haemorrhagic) within 3 months and the primary safety outcome is any severe or moderate bleeding event within 3 months.

Discussion: The CHANCE-2 trial will evaluate whether ticagrelor-aspirin is superior to clopidogrel-aspirin for minor stroke or TIA patients who are CYP2C19 LOF allele carriers.

Trial registration number: NCT04078737.

Keywords: stroke.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
CHANCE-2 study design. CHANCE-2, Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischaemic attack；ASA，aspirin; ULN, upper limit of normal; ALT, alanine aminotransferase; AST，aspartate transaminase；AV, atrioventricular.
Figure 2
Figure 2
Summary of inclusion and exclusion criteria. HR-NICE, high-risk patients with acute non-disabling cerebrovascular events (TIA or acute minor stroke); LOF, loss-of-function.

References

    1. Amarenco P, Lavallée PC, Labreuche J, et al. . One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med 2016;374:1533–42. 10.1056/NEJMoa1412981
    1. Amarenco P, Lavallée PC, Monteiro Tavares L, et al. . Five-year risk of stroke after TIA or minor ischemic stroke. N Engl J Med 2018;378:2182–90. 10.1056/NEJMoa1802712
    1. Wang Y, Wang Y, Zhao X, et al. . Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–19. 10.1056/NEJMoa1215340
    1. Johnston SC, Easton JD, Farrant M, et al. . Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:215–25. 10.1056/NEJMoa1800410
    1. Wang Y, Zhao X, Lin J, et al. . Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA 2016;316:70–8. 10.1001/jama.2016.8662
    1. Meschia JF, Walton RL, Farrugia LP, et al. . Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke 2020;51:2058–65. 10.1161/STROKEAHA.119.028713
    1. Pan Y, Chen W, Xu Y, et al. . Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation 2017;135:21–33. 10.1161/CIRCULATIONAHA.116.024913
    1. Storey RF, Husted S, Harrington RA, et al. . Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852–6. 10.1016/j.jacc.2007.07.058
    1. Wallentin L, Becker RC, Budaj A, et al. . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57. 10.1056/NEJMoa0904327
    1. Wang Y, Minematsu K, Wong KSL, et al. . Ticagrelor in acute stroke or transient ischemic attack in Asian patients: from the SOCRATES trial (acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes). Stroke 2017;48:167–73. 10.1161/STROKEAHA.116.014891
    1. Wang Y, Chen W, Lin Y, et al. . Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ 2019;365:l2211. 10.1136/bmj.l2211
    1. Johnston SC, Amarenco P, Denison H, et al. . Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020;383:207–17. 10.1056/NEJMoa1916870
    1. Meng X, Wang A, Zhang G, et al. . Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial. Stroke & Vascular Neurology 2021;0. 10.1136/svn-2021-000874
    1. GUSTO investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–82. 10.1056/NEJM199309023291001
    1. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. . Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011;4:403–10. 10.1016/j.jcin.2010.12.011
    1. Liu R, Zhou Z-Y, Chen Y-B, et al. . Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. Acta Pharmacol Sin 2016;37:882–8. 10.1038/aps.2016.41
    1. Shuldiner AR, O'Connell JR, Bliden KP, et al. . Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849–57. 10.1001/jama.2009.1232
    1. Han Y, Lv H-H, Liu X, et al. . Influence of genetic polymorphisms on clopidogrel response and clinical outcomes in patients with acute ischemic stroke CYP2C19 genotype on clopidogrel response. CNS Neurosci Ther 2015;21:692–7. 10.1111/cns.12426
    1. McDonough CW, McClure LA, Mitchell BD, et al. . Cyp2C19 metabolizer status and clopidogrel efficacy in the secondary prevention of small subcortical strokes (SPS3) study. J Am Heart Assoc 2015;4:e001652. 10.1161/JAHA.114.001652
    1. Rothwell PM. Antiplatelet treatment to prevent early recurrent stroke. N Engl J Med 2020;383:276–8. 10.1056/NEJMe2018927

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir